Company news
Shanghai MicuRx Pharmaceutical Co., Ltd. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Notice on Convening the 1st Extraordinary General Meeting in 2025
July 1, 2025
Announcement on Reply to Letter of Supervision and Inquiry on Information Disclosure of 2024 Annual Report
June 27, 2025
Announcement on Resolution of the 2024 Annual General Meeting
June 5, 2025
Announcement on the Voluntary Disclosure of Acceptance of the New Drug Application for the Marketing Authorization of Contezolid Acefosamil Sodium for Injection
May 21, 2025
Announcement on Convening the Q1 2025 Performance Briefing
May 19, 2025
Announcement on the Resignation of Independent Directors
May 12, 2025
Report for Q1 2025
April 23, 2025
Announcement on Attending the 2024 SSE STAR Market Innovative Drug Industry Collective Performance Briefing
April 14, 2025
MicuRx: 15 Clinical and Preclinical Research Studies to be Presented at ESCMID Global 2025
April 8, 2025
Announcement on Vesting Results in the 1st Vesting Period of Initial Grant in 2023 Restricted Stock Incentive Plan and Shares Listing
March 20, 2025
Special Report on Deposit and Use of Raised Funds in 2024
March 17, 2025
MicuRx Pharmaceutical: Contezolid Global Phase III Clinical Trial Safety and Efficacy Evaluation Endorsed by Data Monitoring Committee, Promising Prospects for Diabetic Foot Infection Treatment
February 25, 2025
Announcement on Preliminary Earnings Estimate for 2024
February 14, 2025